Results 151 to 160 of about 11,188 (223)

Rethinking law in books versus law in action in China's first experiment of a personal insolvency regime: Towards a more debtor‐oriented procedural design

open access: yesInternational Insolvency Review, EarlyView.
Abstract Although a local experiment, the promulgation of the Regulations of Shenzhen Special Economic Zone on Personal Bankruptcy (SPBR) in 2020 was hailed as a significant milestone in China's insolvency lawmaking which has thus far addressed only corporate insolvencies.
Jenny Fu, Jin Chun
wiley   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang   +13 more
wiley   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park   +11 more
wiley   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

open access: yesInternational Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy